Alnylam Pharma (ALNY) Tops Q1 EPS by 108c, provides guidance

Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of $1.99, $1.08 better than the analyst estimate of $0.91. Revenue for the quarter came in at $1.17 billion versus the consensus estimate of $1.12 billion.

GUIDANCE:

Alnylam Pharma sees FY2026 revenue of $4.9-5.3 billion, versus the consensus of $5.56 billion.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• ShinyHunters hackers say they stole psychiatric and medical records of DBI staff - Reuters
• Bimegren Energy (BESS) files $100M mixed shelf